REGN - REGENERON PHARMACEUTICALS, INC.
IEX Last Trade
1138.9
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:00:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$1,138.90
-428.70
0.60%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-06 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-05 | 2024-05-02 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 27.678 B | 29.215 B | 30.060 B | 30.658 B | 32.163 B | 33.080 B | 34.370 B | 36.087 B | |
| Current Assets | 15.429 B | 15.884 B | 16.909 B | 16.923 B | 18.635 B | 19.479 B | 18.872 B | 19.082 B | |
| Inventories | 2.412 B | 2.402 B | 2.425 B | 2.508 B | 2.562 B | 2.581 B | 2.715 B | 2.874 B | |
| Other Current Assets | 446.400 M | 411.200 M | 406.200 M | 366.300 M | 574.700 M | 386.600 M | 414.900 M | 681.900 M | |
| Short Term Investments | 446.400 M | 411.200 M | 406.200 M | 366.300 M | 574.700 M | 386.600 M | 414.900 M | 681.900 M | |
| Total Receivables | 5.548 B | 5.329 B | 5.119 B | 5.121 B | 5.585 B | 5.667 B | 5.222 B | 5.717 B | |
| Current Cash | 7.022 B | 7.742 B | 8.960 B | 8.928 B | 9.914 B | 10.845 B | 10.520 B | 9.809 B | |
| Total Non-current Assets | 12.249 B | 13.330 B | 13.151 B | 13.735 B | 13.529 B | 13.601 B | 15.498 B | 17.005 B | |
| Property Plant Equipment | 3.704 B | 3.763 B | 3.881 B | 3.923 B | 4.006 B | 4.146 B | 4.226 B | 4.306 B | |
| Other Assets | 320.200 M | 336.400 M | 349.600 M | 393.200 M | 409.900 M | 444.100 M | 470.200 M | 993.800 M | |
| Intangible Assets | 804.100 M | 915.500 M | 928.700 M | 953.000 M | 1.017 B | 1.039 B | 1.059 B | 1.102 B | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 27.678 B | 29.215 B | 30.060 B | 30.658 B | 32.163 B | 33.080 B | 34.370 B | 36.087 B | |
| Total liabilities | 6.239 B | 6.551 B | 6.565 B | 6.640 B | 7.259 B | 7.107 B | 7.379 B | 7.881 B | |
| Total current liabilities | 2.879 B | 3.141 B | 3.100 B | 3.104 B | 3.599 B | 3.423 B | 3.581 B | 3.509 B | |
| Accounts Payable | 535.600 M | 589.200 M | 599.500 M | 547.300 M | 536.600 M | 606.600 M | 671.300 M | 561.700 M | |
| Other liabilities | 658.700 M | 707.800 M | 762.800 M | 833.000 M | 957.700 M | 980.800 M | 1.094 B | 1.669 B | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 2.701 B | 2.701 B | 2.702 B | 2.702 B | 2.703 B | 2.703 B | 2.703 B | 2.704 B | |
| Other liabilities | 658.700 M | 707.800 M | 762.800 M | 833.000 M | 957.700 M | 980.800 M | 1.094 B | 1.669 B | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 21.439 B | 22.664 B | 23.495 B | 24.018 B | 24.904 B | 25.973 B | 26.991 B | 28.206 B | |
| Common stock | 106.900 M | 106.800 M | 107.100 M | 107.000 M | 106.300 M | 106.400 M | 107.800 M | 108.100 M | |
| Retained earnings | 22.110 B | 23.307 B | 24.125 B | 25.093 B | 26.101 B | 27.260 B | 27.982 B | 29.415 B |